These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21150277)

  • 1. Do predictive signatures really predict response to cancer chemotherapy?
    Borst P; Wessels L
    Cell Cycle; 2010 Dec; 9(24):4836-40. PubMed ID: 21150277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel biomarkers in cancer: The whole is greater than the sum of its parts.
    Samatov TR; Galatenko VV; Block A; Shkurnikov MY; Tonevitsky AG; Schumacher U
    Semin Cancer Biol; 2017 Aug; 45():50-57. PubMed ID: 27639751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs.
    Fiebig HH; Schüler J; Bausch N; Hofmann M; Metz T; Korrat A
    Cancer Genomics Proteomics; 2007; 4(3):197-209. PubMed ID: 17878523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CINSARC signature: prognostic and predictive of response to chemotherapy?
    Bertucci F; Finetti P; Sabatier R; Birnbaum D
    Cell Cycle; 2010 Oct; 9(19):4025-7. PubMed ID: 20978372
    [No Abstract]   [Full Text] [Related]  

  • 5. Predicting chemosensitivity using drug perturbed gene dynamics.
    Mannheimer JD; Prasad A; Gustafson DL
    BMC Bioinformatics; 2021 Jan; 22(1):15. PubMed ID: 33413081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
    Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
    Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design.
    Andre F; Mazouni C; Hortobagyi GN; Pusztai L
    Biochim Biophys Acta; 2006 Dec; 1766(2):197-204. PubMed ID: 16962247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular classification and drug response prediction in cancer.
    Creighton CJ
    Curr Drug Targets; 2012 Nov; 13(12):1488-94. PubMed ID: 22974392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics technique predicts chemotherapy success.
    Traynor K
    Am J Health Syst Pharm; 2006 Dec; 63(23):2304-6. PubMed ID: 17105999
    [No Abstract]   [Full Text] [Related]  

  • 10. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
    Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
    Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
    N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Getting the details right: gene signatures for cancer therapy.
    Master SR
    Clin Chem; 2010 Sep; 56(9):1378-80. PubMed ID: 20592045
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical trial methods to discover and validate predictive markers for treatment response in cancer.
    Paik S
    Biotechnol Annu Rev; 2003; 9():259-67. PubMed ID: 14650930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of supervised gene signatures of early hypoxia on patient survival.
    Seigneuric R; Starmans MH; Fung G; Krishnapuram B; Nuyten DS; van Erk A; Magagnin MG; Rouschop KM; Krishnan S; Rao RB; Evelo CT; Begg AC; Wouters BG; Lambin P
    Radiother Oncol; 2007 Jun; 83(3):374-82. PubMed ID: 17532074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conservation of immune gene signatures in solid tumors and prognostic implications.
    Chifman J; Pullikuth A; Chou JW; Bedognetti D; Miller LD
    BMC Cancer; 2016 Nov; 16(1):911. PubMed ID: 27871313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia.
    Raponi M; Harousseau JL; Lancet JE; Löwenberg B; Stone R; Zhang Y; Rackoff W; Wang Y; Atkins D
    Clin Cancer Res; 2007 Apr; 13(7):2254-60. PubMed ID: 17404110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of HSD17B10 and IFITM2.
    Salas S; Jézéquel P; Campion L; Deville JL; Chibon F; Bartoli C; Gentet JC; Charbonnel C; Gouraud W; Voutsinos-Porche B; Brouchet A; Duffaud F; Figarella-Branger D; Bouvier C
    Int J Cancer; 2009 Aug; 125(4):851-60. PubMed ID: 19449377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations.
    Györffy B; Surowiak P; Kiesslich O; Denkert C; Schäfer R; Dietel M; Lage H
    Int J Cancer; 2006 Apr; 118(7):1699-712. PubMed ID: 16217747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies.
    Jiang P; Lee W; Li X; Johnson C; Liu JS; Brown M; Aster JC; Liu XS
    Cell Syst; 2018 Mar; 6(3):343-354.e5. PubMed ID: 29428415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.